

Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon

Amanda Lopes Maia Rodrigues¹, Daniel Macêdo do Nascimento¹, Josy Marinho de Lima², Marcos Laércio Pontes Reis², Lucyana Barbosa Cardoso Leão², Murilo Chermont Azevedo³, Samanta Ribeiro Muccini³, Polyana Castanha da Silva³, Thiago Xavier Carneiro²

¹School of Medical Sciences, Pará State University, Belém – PA, Brazil

²Division of Hematology-Oncology and Stem Cell Transplantation, Ophir Loyola Hospital, Belém – PA, Brazil

³School of Medical Sciences, Federal University of Pará, Belém – PA, Brazil.

Corresponding Author: Amanda Lopes Maia Rodrigues, School of Medical Sciences, Pará State University, Belém – PA, Brazil

Tel: +559131311704

Fax: +559132445460

Email: amandalmrodrigues@gmail.com

Received: 26, Apr, 2019

Accepted: 26, Jan, 2020

ABSTRACT

Background: The attempt to manage patients with acute myeloid leukemia as outpatients has become increasingly common due to high hospitalization costs, low availability for beds and patient preference. Publications on the subject are scarce, especially in low-income regions and the safety in this population remains to be determined. The present study aims to assess the safety of consolidation with high-dose cytarabine in the outpatient setting.

Materials and Methods: We retrospectively analyzed 39 patients who underwent consolidation with high-dose cytarabine, between 2009 and 2018, at Ophir Loyola Hospital, in Belém, Brazil. Patients treated after 2015 were given high-dose cytarabine as outpatients due to the decision of medical staff.

Results: Twenty-seven patients received 76 cycles of cytarabine as outpatients; males were 48.14% of the total population, with a median age of approximately 45 years. The occurrence of delay between cycles was significantly lower among outpatients (48.14% vs. 83.33%, $p = 0.04$). There was no difference in relapse rates, transfusion requirements and non-relapse mortality between both groups. Hospitalization was required in 40.74% of patients during outpatient cycles and 18.51% of blood cultures were positive for pathogens. Non-relapse mortality was significantly higher among patients above 50 years old and treated on an outpatient basis (44.4% vs. 5.60%, $p = 0.03$).

Conclusion: High-dose cytarabine administration on an outpatient basis appears to be safe and effective in a low-income population at the Brazilian Amazon region, but toxicity seems to be increased for patients older than 50 years.

Keywords: Acute myeloid leukemia; High drug dose; Chemotherapy; Outpatient care; Low-income population

INTRODUCTION

Acute Myeloid Leukemia (AML) is an aggressive disease that requires intensive treatment, usually consisting of induction chemotherapy and consolidation with high-dose chemotherapy or stem cell transplantation¹. Multiple cycles of cytarabine at

high doses (6000-18000 mg/m²/cycle) have been used as consolidation treatment of patients with acute myeloid leukemia, especially in patients younger than 60 years, with low risk AML^{2,3,4}.

Due to the potential risk of complications resulting from prolonged neutropenia, post-induction

chemotherapy has traditionally been given on an inpatient basis to patients remaining hospitalized until hematologic recovery⁵. In many countries, an average hospitalization period of 3 to 4 weeks for each cycle is adopted⁶.

Prolonged hospitalization, however, increases treatment costs, leads to persistent exposure to hospital-acquired and often multidrug-resistant organisms and impacts on quality of life, increasing rates of depression and sleep disturbances^{1,7,8}. Outpatient treatment can result in a reduction of hospital stay, shorter duration of febrile neutropenia treatment and fewer nosocomial infections^{9,10,11,12}.

The viability, economic impact and safety of the outpatient regimen for high-dose cytarabine consolidation therapy has been previously assessed^{1,13,14,15,16,17,18,19}, without significant differences in the incidence of complications⁵. None of these reports, however, were performed in low income regions^{20,21}.

The benefits of outpatient treatment are even more relevant in developing countries considering costs, access and hospital bed occupancy²². It is important to assure the feasibility of the outpatient strategy in this setting.

The present study aims to analyze the safety and feasibility of outpatient consolidation with high-dose cytarabine in a low-income population.

MATERIALS AND METHODS

This is a retrospective study carried out at Ophir Loyola Hospital (Belém, Brazil). This is the single public health tertiary hospital for treatment of hematologic malignancies in the state.

Data were obtained by chart review of 39 patients diagnosed with AML treated at this hospital from 2009 to 2018, aged ≥ 16 years, who underwent induction therapy, attained complete remission and received consolidation with high-dose cytarabine at a dose of $3\text{g}/\text{m}^2$, twice a day, on days 1, 3 and 5. For patients above 60 years of age, the dose was reduced to $1\text{g}/\text{m}^2$ in the same schedule.

Patients treated between 2009 and July 2015 received cytarabine as inpatients. After this date, all patients were treated in an outpatient setting. The protocol shift was adopted by the hematology

department, motivated by the high demand and limited bed availability. Registers before 2009 could not be accessed.

Patients were clarified and oriented about their disease and care. Medical and transfusion support to outpatients occurred in a day hospital facility, with all patients being advised to return to the hospital in case of fever ($> 38^\circ\text{C}$) or change in clinical status. Oral antimicrobial prophylaxis consisted of acyclovir $800\text{mg}/\text{day}$, fluconazole $300\text{mg}/\text{day}$ and ciprofloxacin $500\text{mg}/\text{day}$. Transfusion requirements were determined by blood counts and clinical status. The studied variables included sex, age, inpatient/outpatient consolidation, date of consolidation cycles, cycle delay, readmissions, complete remission, relapse and death within 30 days after cytarabine cycle (early death). Statistical analysis was performed using SPSS statistics® software and a p value of 0.05 was used as the cut-off for significance.

This research complies with the National Health Council's Research Guidelines Involving Human Beings (Res. CNS 466/12) and the precepts of the Declaration of Helsinki. Approval was obtained from the Research Ethics Committee of Ophir Loyola Hospital, CAAE 00675318.0.3001.550 and opinion 3.121.297, on January 24, 2019.

RESULTS

Between 2009 and 2018, 12 (30.76%) patients received high-dose cytarabine on an inpatient basis and 27 (69.23%) on an outpatient basis. 58.33% (7/12) of inpatients and 48.14% (13/27) of outpatients were male. Patients receiving outpatient chemotherapy were older than hospitalized patients. Transfusion requirements were slightly higher among outpatients. (Table 1).

Table 1. Patient characteristics, consolidation cycles and transfusion requirements

	Outpatient N = 27	Inpatient N = 12	P
Sex (%)			
Male	48.14%	58.33%	0.59
Age (years)			
Median (range)	45.45 (18.66 - 66.21)	30.24 (16.52 - 51.38)	0.93
Cytarabine cycles			
Median (range)	3 (2 - 5)	3.5 (2 - 5)	-
Red blood cell concentrates			
Mean (range)	4.18 (0 - 14)	2.41 (0 - 12)	0.10
Platelet concentrates			
Mean (range)	12.37 (0 - 54)	10.41 (0 - 50)	0.13

Hospitalized patients received 42 cycles of high-dose cytarabine and outpatients received 76 cycles. The occurrence of delay (> 7 days) in at least one cycle

was significantly higher among inpatients, with similar relapse rates (Table 2).

Table 2. Patients' main outcomes (delay, relapse and early death)

	Outpatient N= 27	Inpatient N = 12	P
Delay (%)	48.14%	83.33%	0.04
Relapse (%)	40.74%	50%	0.42
Early death (%)	18.51%	16.66%	0.63

Therefore, 25% of outpatient cycles (19/76) required a short admission period after cytarabine administration. 18.51% (5/27) presented positive bloodstream culture. Agents identified were: *Escherichia coli* (60% of positive cultures), all resistant to quinolones and sensitive to 4th generation cephalosporins and carbapenems; *Pseudomonas aeruginosa* (20% of positive cultures), susceptible only to colistin; and *Staphylococcus epidermidis* (20% of positive cultures), sensitive to all tested antimicrobials. None of the patients with a positive blood culture died.

The early death rate was similar in both groups, all in remission. No patient had any significant treatment-associated neurotoxicity. However, in outpatients aged 50 years or older, a higher mortality was observed when compared to younger patients. Nonetheless, delays were significantly lower, and all deaths occurred in remission. Transfusion requirements and relapse rates were similar in both groups (Table 3).

Table 3. Main outcomes and transfusion requirements among outpatients aged above and below 50 years

	Age <50 (n = 18)	Age >50 (n = 9)	p
Early death (%)	5.60%	44.40%	0.03
Relapse (%)	50%	22.22%	0.16
Delay (%)	66.66%	11.11%	0.008
Red blood cell concentrates			
Mean (range)	3.55 (0 - 14)	5.44 (0 - 9)	0.44
Platelet concentrates			
Mean (range)	10.72 (0 - 44)	12.88 (0 - 38)	0.07

DISCUSSION

In Brazil, to our knowledge, this is the first report of high-dose cytarabine consolidation on an outpatient basis.

One of the major concerns about implementing this system is the occurrence of delays in administration of cycles, especially due to limitations in access or transportation of patients to the hospital, notably more pronounced in a large country such as Brazil. However, in the present study, significantly lower delays were found among outpatients. This shows that access is probably not a limitation to outpatient consolidation. Other studies also showed a similarity between inpatients and outpatients regarding periodicity¹⁹.

In addition, the occurrence of delays or other complications during outpatient administration could impact the incidence of relapse among patients. In previous studies, however, significantly lower rates of relapse were reported among outpatients (32% vs 77%)¹⁹. There was no difference in relapse rates between groups in our population. The expressive need for transfusion after chemotherapy is also a concern. In this study, outpatients received a few more transfusions but there were no significant differences compared to inpatients, as shown in previous reports⁵. This is probably due to a tendency to adopt early transfusions for outpatients, with less tolerance, while inpatients can be closely watched for longer. It

should be noted that there were no cases of significant bleeding in either group.

Administration of outpatient, high-dose cytarabine could also be limited by the classically reported elevated rate of neurotoxicity associated with treatment (8-20%)²³. In the present study, none of the subjects presented significant neurological signs, reinforcing the findings from previous studies which have already demonstrated lower rates in recent years (0.7%)²³.

The number of cycles requiring hospitalization was similar to that previously reported (28%), although the number of patients admitted was higher (20%)¹⁹. However, transference to the hospital system occurred immediately, reinforcing the safety of this regimen to ensure adequate care for patients' demands. Nevertheless, considering an estimated 40% to 33% reduction of treatment costs when adopting the outpatient regimen^{5,24}, these results suggest a significant economic impact. It's also described a better quality of life among patients that experienced a reduction in the number of hospitalized days²⁵.

The prevalence of positive blood cultures was much lower than previously reported for patients in outpatient consolidation (59%)²⁶, and was close to rates described for hospitalized patients (14%)¹³. Corroborating data from the literature, prophylaxis given to outpatients promotes a greater occurrence of resistance to quinolones, especially during the 2nd

cycle of consolidation²⁷. However, even with the isolation of a multidrug resistant pathogen, reduction of sepsis occurrence in patients treated in the outpatient setting¹⁰ is reinforced, and there was an absence of deaths among patients with positive culture.

The early mortality rate was higher than internationally reported for newly diagnosed patients undergoing induction chemotherapy (4%)²⁸. However, there was no significant difference between inpatients or outpatients, possibly reflecting the expected values in the context of the country's population, according to previous surveys (mortality during consolidation of 21-24%)^{29,30}.

Finally, although there are studies showing the safety of outpatient consolidation in elderly patients^{31,32} using 2 cycles of cytarabine, in our hospital, mortality rates were higher among patients older than 50 years. This is possibly due to a higher prevalence of comorbidities or increased toxicity and infection rates during longer consolidation treatment, evidencing the need for differentiated support strategies and discouraging adoption of this regimen in this specific group of individuals. It is worth mentioning that this research has many limitations. For instance, it is a retrospective analysis based on medical records. In addition, we were unable to directly quantify the economic impact of outpatient treatment. Furthermore, this study represents the situation in a single tertiary hospital, and the results will need to be reproduced in other institutions.

Therefore, high-dose cytarabine administration on an outpatient basis appears to be safe and effective in the context of developing regions, possibly due to significantly reducing costs related to treatment and improving patient's quality of life. However, such a regimen should be used with caution in patients over 50 years due to the high risk of toxicity in this group.

DISCLOSURE OF INTEREST

The authors report no conflict of interest.

REFERENCES

1. Leunis A, Blommestein HM, Huijgens PC, et al. The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. *Leuk Res.* 2013; 37(3):245-50.
2. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. *N Engl J Med.* 2009; 361(13):1235-48.
3. Li W, Gong X, Sun M, et al. High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis. *PLoS One.* 2014; 9(10):e1110153.
4. Briot T, Roger E, Thépot S, et al. Advances in treatment formulations for acute myeloid leukemia. *Drug Discov Today.* 2018; 23(12):1936-49.
5. Aw A, Sabloff M, Sheppard D, et al. Evaluation of an Outpatient Model for Treatment of Acute Myeloid Leukemia. *J Haematol.* 2016; 5(1):1-7.
6. Walter RB, Taylor LR, Gardner KM, et al. Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. *Clin Adv Hematol Oncol.* 2013; 11(9):571-577.
7. Redaelli A, Botteman MF, Stephens JM, et al. Economic burden of acute myeloid leukemia: a literature review. *Cancer Treat Rev.* 2004; 30(3):237-47.
8. El-Jawahri AR, Traeger LN, Kuzmuk K, et al. Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. *Cancer.* 2015; 121(6):951-959.
9. Cox KM, Goel S, O'Connell RL, et al. A randomized crossover trial comparing inpatient and outpatient administration of high dose cisplatin. *Intern Med J.* 2011; 41(2):172-8.
10. Halim TY, Song KW, Barnett MJ, et al. Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia. *Ann Oncol.* 2007; 18(7):1246-52.
11. Gillis S, Dann EJ, Rund D. Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. *Am J Hematol.* 1996; 51(1):26-31.
12. Walter RB, Lee SJ, Gardner KM, et al. Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. *Haematologica.* 2011; 96(6):914-7.
13. Vaughn JE, Othus M, Powell MA, et al. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis. *JAMA Oncol.* 2015; 1(8):1120-7.

14. Savoie ML, Nevil TJ, Song KW, et al. Shifting to outpatient management of acute myeloid leukemia: a prospective experience. *Ann Oncol.* 2006; 17(5):763-8.
15. Irish W, Ryan M, Gache L, et al. Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse. *Curr Med Res Opin.* 2017; 33(3):519-527.
16. Sopko L, Sabty FA, Rimajova V, et al. The feasibility of an early hospital discharge following chemotherapy for the acute myeloid leukemia. *Bratisl Lek Listy.* 2012; 113(5):298-300.
17. Cao XX, Wang SJ, Duan MH, et al. Long-term safety and efficacy of high-dose cytarabine consolidation in patients with acute myeloid leukemia. *Zhonghua Xue Ye Xue Za Zhi.* 2017; 38(4):330-333.
18. Møller T, Nielsen OJ, Welinder P, et al. Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemia. *Eur J Haematol.* 2010; 84(4):316-22.
19. Allen MR, Aljittawi OS, Abhyankar S, et al. Outpatient Cytarabine Administration Is Safe and Effective For Consolidation In Acute Myeloid Leukemia. *Blood.* 2013; 122: 5030.
20. Halpern AB, Walter RB, Estey EH. Outpatient induction and consolidation care strategies in acute myeloid leukemia. *Curr Opin Hematol.* 2019; 26(2):65-70.
21. Reid RM, Baran A, Friedberg JW, et al. Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. *Cancer Med.* 2016; 5(11):3059–3067.
22. O'Donnell O. Access to health care in developing countries: breaking down demand side barriers. *Cad Saude Publica.* 2007; 23(12):2820-2834.
23. Wetzstein GA, Lancet JE, Kallner JE Sivik JM, et al. Safety, feasibility, and cost-effectiveness with outpatient administration of high-dose cytarabine consolidation in acute myeloid leukemia. *Blood.* 2008; 112(11):2405.
24. Eisele L, Günther, F, Ebeling P, et al. Outpatient Management of Acute Myeloid Leukemia after Intensive Consolidation Chemotherapy Is Feasible and Reduces Hospital Treatment Costs. *Onkologie.* 2010; 33(12):658–664.
25. Jarden M, Møller T, Christensen KB, et al. Multimodal intervention integrated into the clinical management of acute leukemia improves physical function and quality of life during consolidation chemotherapy: a randomized trial 'PACE-AL'. *Haematologica.* 2016;101(7):e316-9.
26. Benke S, Bow EJ, Schacter B, et al. Infectious Morbidity and Hospitalization Requirements of Patients with Acute Myeloid Leukemia Receiving Intensive Outpatient Consolidation. *Blood.* 2004; 104(11):4524.
27. Saini L, Rostein C, Atenafu EG, et al. Ambulatory consolidation chemotherapy for acute myeloid leukemia with antibacterial prophylaxis is associated with frequent bacteremia and the emergence of fluoroquinolone resistant *E. Coli*. *BMC Infect Dis.* 2013;13:284.
28. Othus M, Kantarjian H, Petersdorf S, et al. Declining Rates of Treatment-Related Mortality in Patients with Newly-diagnosed AML Given “Intense” Induction Regimens: A Report from SWOG and MD Anderson. *Leukemia.* 2014; 28(2):289–292.
29. Bittencourt R, Fogliato L, Daudt L, et al. Leucemia Mielóide Aguda: perfil de duas décadas do Serviço de Hematologia do Hospital das Clínicas de Porto Alegre - RS. *Rev. Bras Hematol Hemoter.* 2003; 25(1):17-24.
30. Azevedo MC, Velloso EDRP, Buccheri V, et al. Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia. *Braz J Med Biol Res.* 2015; 48(2):178-85.
31. Saini L, Minden MD, Schuh AC, et al. Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia. *Am J Hematol.* 2012; 87(3):323-6.
32. Vives S, Oriol A, Piernas S, et al. Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older. *Eur J Haematol.* 2015; 95(6):576-82.